within Pharmacolibrary.Drugs.ATC.L;

model L02BG05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BG05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Vorozole is a nonsteroidal aromatase inhibitor that was developed for the treatment of hormone-dependent breast cancer. It inhibits the aromatase enzyme, thereby preventing the conversion of androgens to estrogens. Vorozole was investigated in clinical trials but is not approved or marketed for clinical use today, as other aromatase inhibitors have been preferred for clinical development and use.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic publications with reported parameter values for vorozole were identified. The following are estimated parameters based on general properties of similar orally administered nonsteroidal aromatase inhibitors in adults.</p><h4>References</h4><ol><li><p>Wouters, W, et al., &amp; De Coster, R (1994). Vorozole, a specific non-steroidal aromatase inhibitor. <i>Breast cancer research and treatment</i> 30(1) 89–94. DOI:<a href=&quot;https://doi.org/10.1007/BF00682743&quot;>10.1007/BF00682743</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7726994/&quot;>https://pubmed.ncbi.nlm.nih.gov/7726994</a></p></li><li><p>Wiseman, LR, &amp; Adkins, JC (1998). Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. <i>Drugs &amp; aging</i> 13(4) 321–332. DOI:<a href=&quot;https://doi.org/10.2165/00002512-199813040-00008&quot;>10.2165/00002512-199813040-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9805213/&quot;>https://pubmed.ncbi.nlm.nih.gov/9805213</a></p></li><li><p>Piotrovsky, VK, et al., &amp; Langenaecken, C (1998). Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. <i>Cancer chemotherapy and pharmacology</i> 42(3) 221–228. DOI:<a href=&quot;https://doi.org/10.1007/s002800050808&quot;>10.1007/s002800050808</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9685057/&quot;>https://pubmed.ncbi.nlm.nih.gov/9685057</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BG05;
